🇺🇸·8h agoResearch
Nivolumab ± Ipilimumab in Patients With Pretreated Advanced Neuroendocrine Carcinoma: The GCO-001 NIPINEC Randomized Phase II Trial
Publisher
A
ASCO JCO Journal
USA
This page provides a limited summary and publisher metadata to support discovery before sending readers to the original article.
Read originalIn-platform summary, original article off-platform
This page presents the title, publisher metadata, and a limited summary excerpt to help users judge relevance first. Full-text reading stays on the publisher's original site.
Source route
Continue on ascopubs.org
Leave the platform to read the original full article on the publisher site.
Source: ASCO JCO Journal
Scope: Research
Related coverage
More related coverage
UNMC·8h ago
Study suggests link between prenatal exposure to certain medications and increased autism risk
ASCO JCO Journal·8h ago
How Much Is Enough? Ultra-Low Doses of Immunotherapy to Improve Access and Affordability
ASCO JCO Journal·8h ago
Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO Guideline Update
ASCO JCO Journal·8h ago